Baxter completes biopharma solutions sale, business unit revamp

The company plans to use most of the $3.7 billion in after-tax proceeds from the biopharma solutions sale to repay debt.

By Susan Kelly • Nov. 2, 2023

Drilling down on obesity drugs: What medtech executives are saying

Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.

By Susan Kelly • Nov. 2, 2023

GE HealthCare sales resilient despite ‘highly volatile’ economy

The company raised its earnings forecast for 2023 as it outlined plans to expand margins and navigate China's anti-corruption campaign.

By Elise Reuter • Oct. 31, 2023

4 medtech companies to watch this week in earnings

GE HealthCare and Stryker are among the top medtech companies posting financial results in the third week of this earnings season. 

By Susan Kelly • Oct. 30, 2023

Resmed cuts 5% of staff amid profitability push

The company has stopped some projects that were not working well as it seeks to cut operating costs, CEO Mick Farrell told investors. 

By Elise Reuter • Oct. 30, 2023

Edwards reported double-digit Q3 sales growth, but some analysts are skeptical about 2024

Executives answered questions on the Wednesday earnings call about TAVR’s growth potential and results of a key clinical trial, released earlier this week, comparing the procedure to open-heart surgery.

By Ricky Zipp • Oct. 26, 2023

Boston Scientific looks to new devices in 2024 to drive growth

The company expects to receive FDA approval for its Agent drug-coated balloon and its Farapulse pulsed-field ablation system next year.

By Elise Reuter • Oct. 26, 2023

Thermo Fisher cuts 2023 forecast, citing volatile economic conditions

Customer spending remains constrained overall, while economic conditions in China have weakened, CEO Marc Casper said on a Wednesday earnings call.

By Susan Kelly • Oct. 25, 2023

Danaher Q3 revenue declines as demand challenges continue

Better-than-expected respiratory testing revenue was a bright spot, but the company’s overall orders are “bouncing along” at a bottom, CEO Rainer Blair said on a Tuesday earnings call.

By Susan Kelly • Oct. 24, 2023

Philips’ orders fall in Q3, overshadowing sales growth and return to sleep apnea market

CEO Roy Jakobs said during a third-quarter earnings call that there is still “significant demand” for the company’s sleep apnea products.

By Nick Paul Taylor • Oct. 23, 2023

Intuitive’s Q3 sales miss estimates as robot leasing, China demand weigh

The robotic surgery leader’s overall procedure growth, however, exceeded market expectations.

By Susan Kelly • Oct. 20, 2023

Abbott raises outlook amid strong Q3, sees momentum into 2024

Sales of the FreeStyle Libre continuous glucose monitor rose nearly 31% despite investor worries about the potential impact of weight-loss drugs on demand.

By Susan Kelly • Oct. 18, 2023

J&J to restructure orthopedics business

The company announced the two-year restructuring in its third-quarter earnings call. It expects the changes to accelerate growth and enhance profitability, CFO Joe Wolk said.

By Elise Reuter • Oct. 17, 2023

Bad CRM data can cost your MedTech company 10% in annual revenue

Nearly half of all companies with CRM would say, “it doesn’t live up to the hype.” 

By Clari • Oct. 9, 2023

Artificial heart maker’s cash runway shrinks to 1 month after supply woes hurt sales

France’s Carmat expects revenues of up to 6 million euros in the second half of the year but needs to secure financing to avoid running out of money.

By Nick Paul Taylor • Sept. 28, 2023

Medtronic raises earnings forecast amid supply chain, diabetes business improvements

The company also shared an update on the planned divestment of its monitoring and respiratory interventions segments.

By Elise Reuter • Aug. 22, 2023

Cue Health wins $28M BARDA contract to develop rapid respiratory infection test

The company plans to launch the respiratory panel for the 2024-25 virus season and aims to break even in 2025.

By Nick Paul Taylor • Aug. 14, 2023

Illumina shakes up executive team, lowers 2023 outlook

The gene sequencing industry leader, which is operating under an interim CEO, named a new chief technology officer and announced the departure of its chief medical officer.

By Susan Kelly • Aug. 10, 2023

Anne-Françoise Nesmes to step down as Smith+Nephew CFO next year

The announcement comes as Smith+Nephew raised its forecast for the year to a 6% to 7% revenue increase, due to more favorable market conditions. 

By Nick Paul Taylor • Aug. 7, 2023

Stryker raises earnings forecast as procedures return to pre-pandemic levels

The company expects elevated procedure demand to continue into 2024 due to surgery backlogs.

By Elise Reuter • Aug. 4, 2023

BD prepares for relaunch of Alaris pump, raises revenue forecast

The pump relaunch isn’t expected to contribute much to this year’s revenue, but could help Becton Dickinson reach its long-term financial goals. 

By Elise Reuter • Aug. 3, 2023

Varian logistics slow growth at Siemens Healthineers in Q3

Healthineers has worked through some logistics problems but now faces a race to install Varian equipment at customer sites. 

By Nick Paul Taylor • Aug. 2, 2023

Vicarious expects to perform first human procedure with robot next year

The company, after disclosing layoffs in February, said it has gained clarity on its regulatory pathway following pre-submission meetings with the FDA.

By Susan Kelly • July 31, 2023

Integra warns impact of plant closure will continue into 2024, with delays possible

Management has built a buffer into the plan but cautioned unforeseen events could cause its timeline to slip.

By Nick Paul Taylor • July 31, 2023

Thermo Fisher eyes $450M in cost cuts due to slowing demand

The pullback in spending will include layoffs and lower investments in some areas of the business, company executives said.

By Susan Kelly • July 28, 2023